MedTrace Logo

Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C

NCT00148863 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2007-08-30

No results posted yet for this study

Summary

Viral hepatitis C is treated with peg-interferon alpha 2a/2b and ribavirin. There is no treatment recommended for non responders patients. This study will evaluate the efficacy, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 Weeks of the addition of interferon gamma in non responders patients

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Peg-interferon alpha 2a (drug)

DRUG

Ribavirin (drug)

DRUG

Interferon gamma (drug)

Sponsors & Collaborators

  • InterMune

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Patrice Couzigou, MD, PhD · Hôpital du Haut-Lévêque, Pessac, France

  • Geneviève Chêne, MD, PhD · INSERM U593, Bordeaux, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2007-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148863 on ClinicalTrials.gov